Skip to Main Content

INFORMATION FOR

    Jonathan Bogan, MD

    Professor of Medicine (Endocrinology) and of Cell Biology
    DownloadHi-Res Photo

    Are You a Patient?

    View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

    View Doctor Profile

    Additional Titles

    Associate Section Chief, Section of Endocrinology and Metabolism

    About

    Titles

    Professor of Medicine (Endocrinology) and of Cell Biology

    Associate Section Chief, Section of Endocrinology and Metabolism

    Biography

    Dr. Jonathan Bogan is a physician-scientist whose research focuses on understanding mechanisms that regulate glucose uptake and metabolism in fat and muscle. He received a B.S. in electrical engineering from Yale College and an M.D. from Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology. His thesis work in genetics was done with Dr. David Page at the Whitehead Institute/M.I.T., where he contributed to mapping the human Y chromosome. Dr. Bogan did his residency in Internal Medicine and fellowship in Endocrinology at Massachusetts General Hospital. During his fellowship and subsequently as a faculty member at Harvard, he worked with Dr. Harvey Lodish at the Whitehead Institute, and conceptualized and carried out a genetic screen to study insulin action. This work led to several subsequent studies to elucidate how fat and muscle cells regulate protein trafficking and stability to control metabolism. Dr. Bogan joined the Yale faculty in 2002 and is now a tenured Professor of Medicine. Dr. Bogan also holds appointments in the Department of Cell Biology and in the Yale Center for Molecular and Systems Metabolism, and he directs the Cell Biology Core of the Yale Diabetes Research Center. Dr. Bogan has been the recipient of numerous awards, including a NIH Physician-Scientist Award, an American Diabetes Association Career Development Award, and a Smith Family Foundation Award for Excellence in Biomedical Research. He was named a W.M. Keck Foundation Distinguished Young Scholar in Medical Research. Dr. Bogan has been elected to the American Society for Clinical Investigation and Interurban Clinical Club. He has served widely on review panels for the NIH and American Diabetes Association. Dr. Bogan also serves as an Attending Physician at Yale-New Haven Hospital, as co-Director of the Energy and Metabolism Master Course in the M.D. curriculum, and as Assistant Director for Education in the Yale M.D.-Ph.D. Program.

    Appointments

    Education & Training

    Visiting Scientist
    Whitehead Institute for Biomedical Research (2002)
    Fellow
    Massachusetts General Hospital (1997)
    Resident
    Massachusetts General Hospital (1994)
    Intern
    Massachusetts General Hospital (1993)
    MD
    Harvard Medical School (1992)
    BS
    Yale University, Engineering Sciences (Electrical) (1986)

    Research

    Overview

    Dr. Bogan’s laboratory studies molecular mechanisms controlling GLUT4 glucose transporter targeting in adipose and muscle cells. In cell types, insulin stimulates glucose uptake by translocating GLUT4 from intracellular membranes to the cell surface. Understanding how this occurs has been a longstanding puzzle. Dr. Bogan and his coworkers identified proteins that sequester GLUT4 in nonendosomal, intracellular vesicles in the absence of insulin. Insulin then acts on these proteins to mobilize GLUT4 to the cell surface. This action is coordinated with other insulin signals that act on GTPases to direct vesicle targeting. Current work is directed to understand the biochemical mechanisms involved in this response, including phosphorylation, GTPase signaling, and ubiquitin-like modification pathways.

    Much current work in the laboratory focuses on a proteolytic mechanism that regulates glucose uptake in fat and muscle. Previous work identified the TUG protein as a critical regulator of GLUT4 targeting, which limits cell-surface GLUT4 and glucose uptake in cells not stimulated with insulin. TUG traps GLUT4 in non-endosomal vesicles, bound at the Golgi matrix, and insulin triggers site-specific endoproteolytic cleavage of TUG to liberate these vesicles for translocation to the cell surface. GLUT4 and other vesicle cargoes are then maintained at the cell surface by cycling through endosomes, and they bypass a TUG-regulated compartment until insulin signaling is terminated, and the cargoes are re-sequestered. This arrangement obviates the need for ongoing TUG cleavage during sustained insulin exposure. TUG cleavage generates an N-terminal product that functions as a novel ubiquitin-like protein modifier, implicating new enzymatic activities in insulin action. In mice, this proteolytic pathway controls whole-body and muscle-specific glucose uptake, and data show that vesicle cargoes other than GLUT4 contribute to the regulation of vasopressin action and, possibly, lipid metabolism. In addition, the TUG C-terminal product enters the nucleus and regulates gene expression to control fatty acid oxidation, thermogenesis, and overall energy expenditure. Thus, regulated TUG cleavage and vesicle translocation coordinates distinct physiologic outputs, and dysregulation of this pathway may contribute to multiple aspects of the metabolic syndrome and obesity.

    The pathway that is utilized by GLUT4 is likely one instance of a general pathway to regulate the cell surface targeting of membrane proteins in response to extracellular stimuli. Work on GLUT4 targeting may thus have far-reaching implications for a wide range of physiology. In addition, this regulated pathway is likely a cell type-specific adaptation of a fundamental trafficking pathway present in most cells. Current work will elucidate this pathway and how it is adapted to control GLUT4, using a combination of biochemical and cell biological approaches, genetically engineered mice, and studies of organism-level metabolism and physiology.

    Medical Research Interests

    Arginine Vasopressin; Cell Biology; Diabetes Mellitus, Type 2; Endocrinology; Glucose; Glucose Transporter Type 4; Metabolic Diseases; Protein Transport; Thermogenesis; Ubiquitins

    Research at a Glance

    Yale Co-Authors

    Frequent collaborators of Jonathan Bogan's published research.

    Publications

    2024

    2023

    2022

    2021

    2019

    2018

    Academic Achievements & Community Involvement

    • honor

      Elected Fellow of American College of Physicians

    • honor

      Elected member of American Society for Clinical Investigation

    • honor

      W. M. Keck Foundation Distinguished Young Scholar in Medical Research

    Clinical Care

    Overview

    Jonathan S. Bogan, MD’s first objective when providing consultations to inpatients with endocrine disease at Yale New Haven Hospital is to let them know they are not alone. He tells them, “My role is to be your partner in helping you manage your medical issues.”

    “Our practice in the endocrine division at Yale Medicine has very broad clinical expertise, and we see a wide range of patients,” Dr. Bogan says. “We also have a diversity of research on various clinical and basic projects important for endocrine diseases. The high prevalence of these conditions makes it important to understand them.”

    Dr. Bogan is an associate professor of medicine (endocrinology) and of cell biology at Yale School of Medicine. In addition to his clinical practice, he a researcher focused on understanding the development of type 2 diabetes and metabolic syndrome, and how both conditions can be prevented or treated.

    Clinical Specialties

    Endocrinology; Diabetes Medicine & Management

    Get In Touch

    Contacts

    Academic Office Number
    Appointment Number
    Office Fax Number

    Locations

    • Patient Care Locations

      Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

    Events